Febrile neutropenia (FN) risk-assessment and granulocyte-colony stimulating factor (G-CSF) prophylaxis use in clinical practice was evaluated in patients with diffuse large B-cell lymphoma receiving R-CHOP-21. More G-CSF primary prophylaxis was used in patients assessed as high FN risk, but R-CHOP-21 was associated with substantial myelotoxicity in both high- and low-risk groups. In a multivariate analysis, older age, poor performance status, lower baseline hemoglobin, and lack of G-CSF prophylaxis were significantly associated with occurrence of FN in any cycle. Results highlight the need for improved FN risk-assessment and thorough guideline adherence to further reduce FN and better support chemotherapy delivery.

Diffuse large B-cell lymphoma, Febrile neutropenia, Granulocyte colony stimulating factor, R-CHOP-21, Relative dose intensity, Risk assessment
dx.doi.org/10.1016/j.leukres.2012.02.002, hdl.handle.net/1765/62943
Leukemia Research: clinical and laboratory studies
Department of Hematology

Salar, A, Haioun, C, Gaia Rossi, F, Duehrsen, U, Pettengell, R, Johnsen, H.E, … Lugtenburg, P.J. (2012). The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: Findings from clinical practice. Leukemia Research: clinical and laboratory studies, 36(5), 548–553. doi:10.1016/j.leukres.2012.02.002